Core Laboratories NV (CLB) Tops Q3 EPS by 2c; Issues Light Q4 Outlook

Core Laboratories NV (NYSE: CLB) reported Q3 EPS of $1.53, $0.02 better than the analyst estimate of $1.51. Revenue for the quarter came in at $276.14 million versus the consensus estimate of $284.3 million.

Core Laboratories NV sees Q4 2014 EPS of $1.53-$1.56, versus the consensus of $1.6. Core Laboratories NV sees Q4 2014 revenue of $275-280 million, versus the consensus of $292.8 million.

For earnings history and earnings-related data on Core Laboratories NV (CLB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Pfizer lung cancer drug misses survival goal in Phase 3 trial